Ann: Appendix 4C - quarterly and Commentry Q3, page-7

I have spoken recently to Leslie Chong.

The current formulation of the Herr-2 vaccine is not to be modified and is ready to roll with the clinical trials. Steini your interpretation is not only wrong but scurrilous IMO.

Recruitment is slow as both Leslie and Axel Hoos are determined that scientific validation of results - even with relatively small numbers - should be solid and indisputable and this relies on a very tight scientific protocol. The sites are actively searching for appropriate patients with the right stage of disease. I think we need to cut them some slack in terms of time frame but the recruitment is definitely active. If the protocol is too restrictive one would assume the scientific team from IMU should be in a good position to tweak a few things to facilitate recruitment. Remember this has nothing to do with the efficacy of the vaccine.

Tyremen